Free Trial

AC Immune (ACIU) Stock Price, News & Analysis

AC Immune logo
$2.05 -0.02 (-0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 +0.01 (+0.49%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AC Immune Stock (NASDAQ:ACIU)

Key Stats

Today's Range
$2.05
$2.10
50-Day Range
$1.83
$2.45
52-Week Range
$1.43
$3.98
Volume
123,441 shs
Average Volume
154,114 shs
Market Capitalization
$205.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

AC Immune Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

ACIU MarketRank™: 

AC Immune scored higher than 41% of companies evaluated by MarketBeat, and ranked 697th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AC Immune has received no research coverage in the past 90 days.

  • Read more about AC Immune's stock forecast and price target.
  • Earnings Growth

    Earnings for AC Immune are expected to grow in the coming year, from ($0.62) to ($0.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AC Immune is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AC Immune is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AC Immune has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about AC Immune's valuation and earnings.
  • Percentage of Shares Shorted

    2.44% of the float of AC Immune has been sold short.
  • Short Interest Ratio / Days to Cover

    AC Immune has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AC Immune has recently increased by 6.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    AC Immune does not currently pay a dividend.

  • Dividend Growth

    AC Immune does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.44% of the float of AC Immune has been sold short.
  • Short Interest Ratio / Days to Cover

    AC Immune has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AC Immune has recently increased by 6.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    AC Immune has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for AC Immune this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, AC Immune insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of AC Immune is held by insiders.

  • Percentage Held by Institutions

    51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AC Immune's insider trading history.
Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACIU Stock News Headlines

AC Immune Reports Q2 2025 Financial Progress
The stealth altcoin the financial world is underestimating
This DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening RIGHT NOW—this project is poised to see massive moves.... The smart money is already positioning.tc pixel
ACIU AC Immune SA - Seeking Alpha
AC Immune SA (ACIU) - Yahoo Finance
See More Headlines

ACIU Stock Analysis - Frequently Asked Questions

AC Immune's stock was trading at $2.70 at the beginning of 2025. Since then, ACIU shares have decreased by 23.7% and is now trading at $2.06.

AC Immune (NASDAQ:ACIU) issued its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.05. The company earned $1.65 million during the quarter, compared to the consensus estimate of $1.98 million. AC Immune had a negative trailing twelve-month return on equity of 49.35% and a negative net margin of 174.94%.

AC Immune (ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

AC Immune's top institutional shareholders include Marshall Wace LLP (0.14%), Handelsbanken Fonder AB (0.10%), Sei Investments Co. (0.02%) and Group One Trading LLC.

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Meta Platforms (META), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Tesla (TSLA), Advanced Micro Devices (AMD) and Canopy Growth (CGC).

Company Calendar

Last Earnings
8/05/2025
Today
8/28/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACIU
CIK
1651625
Employees
140
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$12.00
Potential Upside/Downside
+480.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.83 million
Net Margins
-174.94%
Pretax Margin
-176.80%
Return on Equity
-49.35%
Return on Assets
-23.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.33
Quick Ratio
1.33

Sales & Book Value

Annual Sales
$28.92 million
Price / Sales
7.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
2.30

Miscellaneous

Outstanding Shares
100,410,000
Free Float
95,791,000
Market Cap
$207.75 million
Optionable
Optionable
Beta
1.65
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ACIU) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners